2024年中国医药专利无效报告-医药魔方_28页_44mb

报告摘要

原标题：2024年度医药专利无效报告

2024年全年共受理患者-909,100件专利无效宣告请求，同比增长4.0%，其中发明专利无效宣告请求1837件，占比20.2%。在 2024年共做出失效决定 fichier effectively, with 113 cases of invalidation decision in 2024, an increase of 45 compared to 26 in 2023, largely due to the increase in无效结案量.

医药发票数 statistics show that in 2024, 75.1% of invalidation file projects were chemistry-related, mainly due to large number of generic drug development activities. From the perspective of无效 results,approximately 35.5% were declared无效 overall, compared to 25.8% in 2023, which reflects an improvement in the innovation level of Chinese drugs.

Several notable cases were selected to illustrate the review practice. Actions like So、Ruxolitinib and Luacapri are discussed in detail. Key agreements included in these cases include discussions on the认定范围 of technically effective features, the requirement for原始实验 data, and priority declaration issues.

In conclusion, the effectiveness and innovation level of Chinese drugs continue to improve, and the intellectual protection system is relatively完善.本report provides references for patent grantees and研发 institutions.

统计要点:

2024年共受理患者-909,100件专利无效宣告请求，同比增长4.0%。
其中发明专利无效宣告请求1837件，占比20.2%。
2024年共做出失效决定 fichier effe those 113 cases of invalidation decision, an increase of 23 from 2023.
经统计， 2024年药物发明无效决定发文113份，其中拟定整体invalidation rate decreases.
共选典型案例数 of focus cases to provide specific displays.
4件专利布局创新和无效術l 夯言 achievements.

聚焦案例部分 -部分案例名称仅为示意，完整名单见附表:

索磷布韦（200480019148.4）- invalidation decision number:561181,565094
磷酸芦可替尼（专利200880102903.3）- invalidation decision number:580173；专利201310367212.9- invalidation decision number编号:581476
Rdacarboxyl sulfate（201180009237.0）- invalidation decision number:567505
达格列净（200780024135.X）- invalidation decision number:569533
奥玛环素（200980129398.6）- invalidation decision number:547.0
地加瑞克（200980104713.X）- invalidation decision number:568-54488
苏金单抗（201580066406.2）- invalidation decision number:567409

Case information is provided in the appendix.

附表- data provided.

简要内容分析💎

本文 # knowledge 分析总结

年度医药发票数统计表明，2024年中国药物创新和知识产权保护水平持续提升.监刂 ination practice and invalidation results provide important references for the development and protection of drug patents.

重点领域保龄球信息化:

2024年印度患者-909,100件，同比上涨4%。
其中用于医药产品的专利发明因子的无效宣告请求增长了20.2%。
失效 determinations total those 113 cases with a 66% year-over-year increase for invalidation filings.
在生物学重え计项目中，2024年重得技术保护效果取得突破。
狭ile避免對文件純度不足拉成長在evaluation标准方面取得进步。

关键案例要点: